Global Feminine Hygiene Products Market

Healthcare fabrics refer to a technical textile with a focus on fiber-based goods used in healthcare settings for hygiene, prevention, and care that may also be antimicrobial, which guards against bacterial growth on the fabric. Healthcare fabrics are made from versatile fibrous fabrics and structures and are utilised in a medical environment either for the medication of an injury or for the arranging of an appropriate condition in clinical treatment. The main healthcare fabrics' raw materials include polypropylene, cotton, polyester, viscose and polyamide. Polypropylene is a flexible resin polymer and is used in absorbable dressings, as absorbents, and in the packaging of medical liquids. The different healthcare fabrics types include non-woven, woven, and knitted, which are used for applications such as dressing products, clothing, hygiene products, wall coverings, privacy curtains, bedding, blankets, and other applications. The healthcare fabrics market research report is one of a series of new reports from The Business Research Company that provides healthcare fabrics market statistics, including healthcare fabrics industry global market size, regional shares, competitors with healthcare fabrics market share, detailed healthcare fabrics market segments, market trends and opportunities, and any further data you may need to thrive in the healthcare fabrics industry. This healthcare fabrics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global healthcare fabrics market size grew from $18.36 billion in 2022 to $20.08 billion in 2023 at a compound annual growth rate (CAGR) of 9.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The healthcare fabrics market size is expected to grow to $29.19 billion in 2027 at a CAGR of 9.8%. Increasing government initiatives towards hygiene are driving the growth of the healthcare fabrics market. Governments across the world are focusing on improving consumer awareness of hygiene and health issues. Medical textiles are used in various areas such as bedding, clothing, surgical gowns, cloth wipes, diapers, and others, which increases demand for antimicrobial textiles and healthcare fabrics. Hygiene issues influence buyers to purchase sustainable antimicrobial textiles that are built of pure fibres with a herbal finish. For instance, in 2021, in India, the Total Sanitation Campaign (TSC) has been working on expanding the awareness of female hygiene products in villages. These initiatives will play a pivotal role in expanding the use of hygiene products, which constitute an application area for healthcare fabrics. Hence, increasing government initiatives are expected to drive the market during the forecast period. Healthcare fabric companies are increasingly focusing on developing sustainable fabrics for use in the healthcare industry. Companies are focusing on manufacturing fabrics that pose low environmental risk and emit fewer carbon dioxide and other greenhouse gases. For instance, in 2021, a US-based coated fabrics company, Precision Textiles, launched a new eco-friendly fabric for use in personal protective equipment (PPE) called EcoGuard. The material contains an additive that helps it biodegrade up to 99% more quickly than typical polypropylene gown material. The isolation gowns made of polypropylene materials take over 600 years to biodegrade in a landfill, whereas the EcoGuard material accelerates the biodegradation process by approximately six years. In March 2021, SHL Healthcare AB, a Sweden-based healthcare products manufacturing company, announced a strategic partnership with NordShield, a Finland-based company specializing in the development of antimicrobial solutions. Through this collaboration, both companies agreed to develop and commercialize healthcare textiles incorporating natural material-based microbial protection. The textile products would satisfy the expanding demand for high-quality, long-lasting antimicrobial solutions in the medical industry. Major players in the healthcare fabrics market are Knoll, Inc., Brentano Inc., Kimberly-Clark Corporation, Avgol Industries 1953 Ltd., Paramount Tech Fab Industries, Advanced Fabrics, Carnegie Fabrics, Herculite, Berry Global Group Inc., Carnegie Fabrics LLC, Eximus Corporation, Herman Miller, Inc., Standard Textile Co., Inc., Arc-Com, Trelleborg Engineered Coated Fabrics, Fabrico, Bally Ribbon Mills, and Precision Fabric Group, Inc. Europe was the largest region in the healthcare fabrics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the healthcare fabrics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the healthcare fabrics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The healthcare fabric market consists of sales of woven fabric, non-woven fabric, polyurethane, dressing clothes, surgical clothes, polyvinyl chloride, and butylene esters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global healthcare fabrics market is segmented - 1) By Raw Material: Polypropylene, Cotton, Polyester, Viscose, Polyamide 2) By Fabric Type: Non-woven, Woven, Knitted 3) By Application: Dressing Products, Clothing, Hygiene Products, Wall Coverings, Privacy Curtains, Bedding And Blankets, Other Applications

The superabsorbent polymer refer to a water-absorbing polymer that can absorb and retain extremely large amounts of a liquid relative to its mass. It is used as an absorbent for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar applications. The main types of superabsorbent polymers are sodium polyacrylate, polyacrylate/polyacrylamide, and copolymers. Sodium polyacrylate refers to the superabsorbent polymers that contain sodium atoms and distributes equally between the network and the water. The different superabsorbent polymer production methods include suspension polymerization, solution polymerization, and gel polymerization which are used for applications such as personal hygiene, packaging, construction, oil and gas, and other applications. The superabsorbent polymers market research report is one of a series of new reports from The Business Research Company that provides superabsorbent polymers market statistics, including superabsorbent polymers industry global market size, regional shares, competitors with a superabsorbent polymers market share, detailed superabsorbent polymers market segments, market trends and opportunities, and any further data you may need to thrive in the superabsorbent polymers industry. This superabsorbent polymers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global superabsorbent polymers market size grew from $8.63 billion in 2022 to $9.19 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The superabsorbent polymers market size is expected to grow to $11.73 billion in 2027 at a CAGR of 6.3%. Increasing awareness about personal hygiene and cleanliness is driving the superabsorbent polymers market. Superabsorbent polymers are primarily used as absorbents for water and aqueous solutions for diapers, adult incontinence products, feminine hygiene products, and similar applications. Thus, the increasing awareness about personal hygiene and cleanliness is expected to drive the market. For instance, 55% of Indian consumers intend to buy more personal hygiene and safety products because of the COVID-19 pandemic, hence aiding market growth during the period. Strategic collaboration between companies are shaping the superabsorbent polymers market. Companies in the superabsorbent polymers market are focusing on strategic collaborations to expand their market share. For instance, in 2020, Japan-based chemical manufacturing company, Nippon Shokubai Co., Ltd. collaborated with Japanese consumer goods company, LiveDo Corporation, and Japanese diaper recycling company, Total Care System Co., Ltd. to jointly develop a variety of technologies for recycling superabsorbent polymers (SAPs) in used diapers. The technology can be applied to a wide variety of SAPs distributed worldwide and promote recycling disposable diapers. In August 2021, Danimer Scientific, Inc., a US-based manufacturer of biopolymers acquired Novomer, Inc. for $152 million. The acquisition is expected to accelerate Danimer Scientific’s strategy to deliver their clients with high-quality biopolymer products. Novomer, Inc. is a US-based chemical conversion technology developing company. Major players in the superabsorbent polymers market are BASF, Nippon Shokubai Co. Ltd., Formosa Plastic Corporation, LG Chem LTD., Sumitomo Seika Chemicals Co. Ltd., SDP Global Ltd., Songwon Industrial Co. Ltd., KAO Corporation, Evonik Industries AG, Yixing Danson Technology, Quan Zhou Banglida Technology Industry Co. Ltd., Shandong Nuoer Biological Technology Co. Ltd., Wanhua Chemical Group Co. Ltd., Sinofloc Chemical Ltd., and SNF Limited Asia- Pacific was the largest region in the superabsorbent polymers market in 2022. Asia-Pacific is expected to be the fastest-growing region in the market. The regions covered in the superabsorbent polymers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the superabsorbent polymers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The superabsorbent polymer market consists of sales of cross-linked polyacrylamides and polyacrylates and cellulose- or starch-acrylonitrile graft copolymers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global superabsorbent polymers market is segmented - 1) By Type: Sodium Polyacrylate, Polyacrylate/Polyacrylamide, Copolymers 2) By Production Method: Suspension Polymerization, Solution Polymerization, Gel Polymerization 3) By Application: Medical, Personal Hygiene, Packaging, Construction, Oil And Gas, Other Applications

The technical textiles refer to engineered products with a definite functionality. Technical textiles are the type of semi-finished or finished textiles or fabric designed especially for the non-decorated purpose. Technical textiles are manufactured using non-woven or woven natural as well as synthetic fibers, which are used due to their excellent technical and functional properties. The main types of materials in technical textiles are natural fiber, synthetic polymer, regenerated fiber, mineral, and metal. Natural fibers are directly obtainable from an animal, vegetable, or mineral source. The different processes include woven, knitted, and non-woven which are used for a variety of applications including transport textiles, medical and hygiene textiles, industrial products and components, agriculture, horticulture, and fishing, home textiles, clothing components, and packaging and containment. The technical textiles market research report is one of a series of new reports from The Business Research Company that provides technical textiles market statistics, including technical textiles industry global market size, regional shares, competitors with a technical textiles market share, detailed technical textiles market segments, market trends and opportunities, and any further data you may need to thrive in the technical textiles industry. This technical textiles market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global technical textiles market size grew from $201.71 billion in 2022 to $213 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, and affecting many markets across the globe. The technical textiles market size is expected to grow to $267.61 billion in 2027 at a CAGR of 5.9%. The increasing demand for technical textiles from end-users is expected to drive the demand in the forecast period. The increase in demand for medical apparel and raising awareness of hygiene products are driving the market. Increasing military expenditure and a rise in local extremist insurgencies and casualties will boost the demand for protective ballistic armors, thus increasing the demand for technical textiles globally. For instance, the Australian Government’s 2019-20 defense budget increased by A$2.3 billion ($1.6 billion) to A$38.7 billion ($27.52 billion) and A$175.8 billion ($125.02 billion) in 2022-23. Hence, the increasing demand from various end-use industries is expected to significantly contribute to the growth of the technical textiles market. Modern technological advancement and continuous innovations are shaping the technical textiles market. Interconnected biometric garments act as connected textiles to collect data on emissions from the respiratory systems, providing new ways to assess the health and performance of the user. For instance, in 2021, Canada-based textile computing leader Myant Inc. launched new designs for connected personal protective equipment that uses volatile organic compound (VOC) sensing and assesses health and performance as a part of its interconnected system of biometric garments. In May 2020, The Freudenberg Group company, a Germany-based technology group, whose products include housewares and cleaning products, automobile parts, textiles, building materials, and telecommunications, agreed on making a strategic investment through the acquisition of acquired UK based Low and Bonar PLC. This acquisition would engage using leading-edge technologies to develop and manufacture its fabrics and textiles and for refining textiles and materials by maintaining top quality in the products. Low and Bonar PLC, is a UK-based company, which is engaged in the manufacture and supply of performance technical textiles and technically coated fabrics. Major players in the technical textiles market are Asahi Kasei, Kimberly Clarke, Berry Global Group, DuPont, Mitsui Chemicals, Freudenberg and Co., Low and Bonar, Huntsman, Toyobo Co., Milliken and Company, SRF Limited, International Textile Group, Koninklijke Ten Cate, 3M, Ahlstrom, Johnson and Johnson, Procter and Gamble, SKAPS, Baltex, Johns Manville, Companhia Providência, Fiberweb PLC, Strata Geosystems Pvt. Ltd., The TWE Group, Lanxess, Ibena Textilewerke GmbH, Maccaferri, Duvaltex, Hindoostan Mills, GSE Environmental Inc., and Polymer Group Inc. Asia-Pacific was the largest region in the technical textiles market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the technical textiles market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the technical textiles market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The technical textiles market consists of sales of raw materials for technical textiles such as natural fibers, regerated fibers and synthetic fibers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global technical textiles market is segmented - 1) By Material: Natural Fiber, Synthetic Polymer, Regenerated Fiber, Mineral, Metal 2) By Process: Woven, Knitted, Non-woven 3) By Application: Transport Textiles, Medical And Hygiene Textiles, Industrial Products And Components, Agriculture, Horticulture, And Fishing, Home Textiles, Clothing Components, Packaging And Containment

The cardiovascular drugs market consists of sales of cardiovascular drugs by entities (organizations, sole traders and partnerships) that produce cardiovascular drugs to treat cardiovascular diseases. This industry includes establishments that produce anti-hypertensive drugs to prevent heart failure by controlling blood pressure and hypolipidemic drugs that reduce lipid and lipoprotein levels in the blood. It also consists of establishments which produce antithrombotic drugs to treat arterial and venous thrombosis. The main types of cardiovascular drugs market are anti-hypertensive drugs, hypolipidemics, anti thrombotics, and other drugs for cardiovascular diseases (congestive heart failure, anti-arrhythmic and anti-anginal drugs). Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global cardiovascular drugs market size is expected to grow from $146.51 billion in 2021 to $153.60 billion in 2022 at a compound annual growth rate (CAGR) of 4.8%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The cardiovascular drugs market is expected to reach $205.71 billion in 2026 at a CAGR of 7.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of cardiovascular diseases including hypertension. According to the World Health Organization, chronic disease prevalence is rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the cardiovascular drugs market during the forecast period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of cardiovascular drugs market manufacturers. NOACs are gaining wider acceptance and are replacing traditionally used anti-coagulants such as Warfarin and Heparin. Anti-coagulants have long been used in prevention of thrombus formation in patients suffering with cardiovascular diseases. Use of NOACs makes it easier for patients to continue therapy post discharge as opposed to injections of Heparin and Warfarin which need medical assistance for administration. Some of the NOACs include Pradaxa (dabigatran etexilate) from Boehringer Ingelheim, Xarelto (rivaroxaban) from Janssen, and Eliquis (apixaban) from Bristol-Myers Squibb. Major companies in the cardiovascular drugs market include Medtronic Inc., Boston Scientific Corporation, Abbott Laboratories, Edwards Lifesciences, Cardinal Health, Inc., Johnson & Johnson, Terumo Corporation, Getinge Group, Teleflex Inc. and Becton Dickinson. North America was the largest region in the cardiovascular drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the cardiovascular drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiovascular drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global cardiovascular drugs market is segmented - 1) By Type: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs for Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic and Anti-Anginal Drugs) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The dermatology drugs market consists of sales of dermatology drugs by entities (organizations, sole traders and partnerships) that produce dermatology drugs to treat skin diseases. This industry includes establishments that produce drugs to treat diseases such as rosacea, dermatitis, hyperhidrosis, androgenic alopecia, acne drugs, microbial infections and other skin disorders. The main types of dermatology drugs are acne drugs, dermatitis, psoriasis, and other drugs for dermatology diseases. Psoriasis is a skin condition that causes red, itchy scaly patches on the knees, elbows, trunk, and scalp. Hypolipidemic drugs are a diverse class of medications used to treat high levels of fats (lipids) in the blood, such as cholesterol (hyperlipidemia). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global dermatology drugs market size is expected to grow from $49.55 billion in 2021 to $54.54 billion in 2022 at a compound annual growth rate (CAGR) of 10.1%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The dermatology drugs market is expected to reach $117.82 billion in 2026 at a CAGR of 21.2%. The dermatology drugs market was mainly driven by rapid growth in emerging markets in the historic period. Emerging markets growth was aided by rising disposable income, stable political environment and increasing foreign investments in these countries. For instance, according to the IMF, China’s GDP growth rate was 2.3% in 2020. Additionally, according to the World Economic Outlook Reports by the IMF, the global growth is 6% in 2021 and expected to be 4.4% in 2022. Thus, strong economic growth boosted the demand for dermatology drugs and this drove the market during the historic period. High costs associated with drugs is a major issue faced by citizens of many countries. Pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. In less wealthy countries, lack of cost-effective drugs has influenced the health conditions of the population and has led to a low average life expectancy. As a result, in countries such as Chad, Macedonia, Serbia, the pharmaceutical companies are faced with the pressure of reducing the price of drugs. The high costs associated with drugs are putting pressure on the revenues of dermatology drugs manufacturers. Drug manufacturing companies are using genome testing (genetic diagnosis) to reduce the time and costs spent in clinical trials. A clinical trial is a complex process and it often takes months for a drug to be available in the market. This deprives patients of cost-effective treatment. Researchers in the Rockefeller University used genomic testing and data analytics to predict the response of psoriasis patients for a given treatment. Genomic testing algorithms collect gene-expression data from skin biopsies and detect activity in 50,000 different genes. This technique can predict the response of a patient with an accuracy of 95% and within 12 weeks, thus saving significant time for clinical trials and the launch of new drugs. Major companies in the dermatology drugs market include Amgen, Reckitt Benckiser Group plc, AbbVie, Galderma S.A., LEO Pharma A/S, Bayer AG, GlaxosmithKline, Eli Lilly And Company, Novartis AG and Perrigo Company Plc. North America was the largest region in the dermatology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the dermatology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the dermatology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global dermatology drugs market is segmented - 1) By Type: Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The gastrointestinal drugs market consists of sales of gastrointestinal drugs by entities (organizations, sole traders and partnerships) that produce gastrointestinal drugs to treat gastrointestinal diseases such as ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant. The main types of gastrointestinal drugs are antacids, antiulcerants, vitamin and minerals, antiobesity, antiemetics and antinauseants and antidiarrhoeals. Antacids are medications that counteract (neutralise) stomach acid to relieve indigestion and heartburn. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global gastrointestinal drugs market size is expected to grow from $71.85 billion in 2021 to $75.63 billion in 2022 at a compound annual growth rate (CAGR) of 5.3%. The change in the gastrointestinal drugs market growth trend is mainly due to the companies stabilizing their output after catering to the demand that grew exponentially during the COVID-19 pandemic in 2020. The gastrointestinal drugs market is expected to reach $105.51 billion in 2026 at a CAGR of 8.7%. The aging population profile of most countries will contribute to the growth of the gastrointestinal drugs market. The increase in patient pool due to rising geriatric population globally, will contribute significantly to the growth of the market during the forecast period. According to the WHO, by 2030, one in every six people on the planet will be 60 or older. The proportion of the population aged 60 and up will rise from 1 billion in 2020 to 2.2 billion by 2050. This rise in the geriatric population increased the demand for medical care and drove the healthcare expenditure. This will led to increased demand for pharmaceuticals products, significantly impacting market growth during this period. During the forecast period, the growth of the gastrointestinal drugs market will be restrained by patent expiration of branded gastrointestinal drugs. In general, pharmaceutical companies invest a large sum of money in the drug development process and patents. During the patency period, the company holding the patent holds exclusivity for the manufacturing and distribution of drugs. Post expiration of patency, generic versions of the drugs are manufactured by other companies with prices much lower than the original branded drugs. Overall, this will negatively impact the growth of the market in terms of value. Major companies in the gastrointestinal drug industry are investing in making oral capsules of macromolecular drugs for gastrointestinal diseases for making the drug more effective. Macromolecular drugs, such as peptides, proteins, and antibodies, form a new class of drugs which can treat diseases of the gastrointestinal tract, such as inflammatory bowel disease. These macromolecular drugs are usually injected and only a fraction of the administered dose reaches the disease sites in the gastrointestinal tract. Thus, major companies such as Eli Lilly have been increasingly investing in making oral capsules for macromolecular drugs. The company invested $5 million to enter into a collaboration with Entrega to study the oral delivery of complex molecules, such as peptides to combat gastrointestinal diseases. Major companies in the gastrointestinal drugs market include Takeda Pharmaceuticals, Bayer AG, Abbott Laboratories, Otsuka Holdings Co ltd, Johnson & Johnson, Reckitt Benckiser Group plc, Bausch Health Companies Inc., Sanofi S.A, Procter & Gamble and Daiichi Sankyo Company. North America was the largest region in the gastrointestinal drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the gastrointestinal drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the gastrointestinal drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global gastrointestinal drugs market is segmented - 1) By Type: Antacids, Antiulcerants, Vitamin and Minerals, Antiobesity, Antiemetics and Antinauseants, Antidiarrhoeals 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The hematology drugs market consists of sales of hematology drugs and related services by entities (organizations, sole traders and partnerships) that produce hematology drugs to treat diseases such as genetic disorders, anemia, and other related diseases. This industry includes establishments that produce blood products such as red blood cells, white blood cells, platelets, and fresh frozen plasma. It also consists of establishments which produce of anemia and other blood disorder drugs to treat anemia, hemophilia and blood clots. The main types of hermatology drugs are blood products, anemia and other blood disorder drugs. Any therapeutic substance derived from human blood is referred to as a blood product, which includes whole blood and other blood components for transfusion as well as plasma-derived medicinal products. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The global hematology drugs market size is expected to grow from $33.06 billion in 2021 to $36.13 billion in 2022 at a compound annual growth rate (CAGR) of 9.3%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The hematology drugs market is expected to reach $73.67 billion in 2026 at a CAGR of 19.5%. The hematology drugs market growth is aided by stable economic growth forecasted in many developed and developing countries. The International Monetary Fund (IMF) stated that the global GDP growth rate was 3.3% in 2020 and 3.4% in 2021. Recovering commodity prices, after a significant decline in the historic period is further expected to aid the market growth. Developed economies are also expected to register stable growth during the forecast period. Additionally, emerging markets are expected to continue to grow slightly faster than the developed markets in the forecast period. This is expected to increase spending on healthcare services, thereby driving the demand for hematology drugs. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies during the historic period. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin, which negatively impacted the attractiveness of the hematology drugs industry in the historic period. Tranexamic acid is increasingly being used to prevent postpartum hemorrhage (blood loss of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its low price and wide availability. Tranexamic acid is an antifibrinolytic drug that helps in reducing bleeding in surgical and trauma patients, including women with postpartum hemorrhage. According to the World Maternal Antifibrinolytic (WOMAN) trial, using tranexamic acid within three hours of childbirth lowered death from bleeding by 31% and reduced the need for laparotomy (emergency bleeding control surgery) by 36%. The trial included over 20,000 women from 193 hospitals in 21 countries. Major companies in the hematology market include Amgen, Alexion Pharmaceuticals, Bayer AG, F. Hoffmann-La Roche Ltd., CSL, Takeda Pharmaceuticals, Novo Nordisk, Sanofi S.A, Daiichi Sankyo Company and Pfizer Inc. North America was the largest region in the hematology drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the hematology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hematology drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global hematology drugs market is segmented - 1) By Type: Blood Products, Anemia and Other Blood Disorder Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs

The metabolic disorders drugs market consists of sales of metabolic disorders drugs and related services by entities (organizations, sole traders and partnerships) that produce metabolic disorders drugs to treat metabolic diseases. This industry includes establishments that produce drugs such as insulin, pramlintide and other drugs to treat diabetes, anti-thyroid drugs to treat hyperthyroidism, and other drugs to treat pituitary gland, adrenal gland and parathyroid gland disorders. The main types of metabolic disorders drugs are anti diabetics drugs, anti-thyroid drugs and others (hyperparathyroidism, hypopituitarism, hypoadrenalism). Antithyroid drugs are medications that either reduce thyroid hormone synthesis (thionamides) or increase thyroid hormone release (iodides). The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores and others. The global metabolic disorders drugs market size is expected to grow from $82.05 billion in 2021 to $90.83 billion in 2022 at a compound annual growth rate (CAGR) of 10.7%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The metabolic disorders drugs market is expected to reach $205.11 billion in 2026 at a CAGR of 22.6%. The rise in sedentary jobs, busy lifestyles and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as diabetes and obesity. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of metabolic disorders. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. These factors are expected to increase the patient pool globally, thereby driving the metabolic disorders drugs market during the forecast period. Regulatory agencies and federal governments adopted stringent regulations and took a tough stance on drug pricing by pharmaceutical companies. Pharmaceutical companies faced criticism from politicians, patients and physicians over high pricing of some medicines and drugs. Moreover, companies had to sell drugs and medicines at subsidized rates to government hospitals, doctors and clinics, further effecting companies’ revenues. This led to drug manufacturing companies operating on a reduced profit margin. Such factors will negatively impact the attractiveness of the metabolic disorders drugs industry during the forecast period. Companies are focusing on employing artificial intelligence applications to revolutionize the treatment of metabolic disorders. Artificial Intelligence is a machine-based learning which makes use of human intelligence functionalities like reasoning and problem-solving abilities to obtain insights and provide useful information. This technology radically changes the treatment of metabolic syndrome by analyzing large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. 3BIGS, a Korean biodata analysis-based company that studies the relation between diseases, targets and drugs is using AI technology to help researches repurpose the drugs for additional diseases. Major companies in the metabolic disorders drugs market include Novo Nordisk, Eli Lilly And Company, Novartis AG, Sanofi S.A, Merck & Co, GlaxosmithKline, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH and Dainippon Sumitomo Pharma. North America was the largest region in the metabolic disorders drugs market in 2021. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the metabolic disorders drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the metabolic disorders drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The global metabolic disorders drugs market is segmented - 1) By Type: Anti Diabetics Drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism) 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others 3) By Route of Administration: Oral, Parenteral, Others 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs